| Maria C. Barin | |
|---|---|
| Photo placeholder | |
| Affiliations | University of Sao Paulo |
| Country | Brazil |
| H-index | 40 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Neuroinflammation, Neuroepidemiology |
Maria C. Barin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Maria C. Barin is a leading researcher in the field of neurodegenerative diseases, affiliated with the University of Sao Paulo in Brazil. Her research focuses on neuroepidemiology and neuroinflammation, with particular emphasis on Alzheimer's disease.[1] With an h-index of 40, Dr. Barin is among the most cited researchers in the neuroscience field in Brazil and Latin America.[2]
Dr. Barin's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's disease, Parkinson's disease, and related dementias. Her research group has made significant contributions to the fields of neuroepidemiology and translational biomarker research, publishing in high-impact journals including leading neuroscience journals.[3]
Based at the University of Sao Paulo, Dr. Barin collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.[4]
Dr. Barin has developed research programs that bridge basic neuroscience, translational biomarker work, and clinical research. Across her career at the University of Sao Paulo, her group has helped define how mechanistic discoveries are converted into robust disease models and clinically actionable hypotheses.[5]
The laboratory's approach combines rigorous experimental design with broad collaboration across disease-focused teams. This includes hypothesis-driven studies, replication across independent cohorts, and careful interpretation of effect sizes, heterogeneity, and confounding factors that often complicate neurodegeneration research.[6]
Dr. Barin has trained numerous graduate students and postdoctoral researchers, many of whom have gone on to establish independent research programs in neuroscience and neurology. Her mentorship has contributed to building research capacity in neurodegeneration across Latin America.[7]
Dr. Barin's epidemiological research has focused on identifying risk factors for Alzheimer's disease and other dementias in Latin American populations. Her work has highlighted the importance of considering population-specific genetic backgrounds, environmental exposures, and healthcare access disparities in understanding disease burden.[8]
Her translational research has contributed to the validation of fluid biomarkers for Alzheimer's disease diagnosis and progression monitoring. This includes studies on phosphorylated tau (p-tau-181), p-tau-217, and [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- ratios in cerebrospinal fluid and blood.[9]
Dr. Barin has investigated the role of neuroinflammation in neurodegenerative disease pathogenesis. Her work has examined how inflammatory markers correlate with disease progression and treatment response in Alzheimer's disease patients.[10]
Current priorities in Dr. Barin's research ecosystem include:
Improving reproducibility across cohorts through standardized protocols and quality control measures. This includes harmonizing biomarker assays across different laboratories and implementing blind sample analysis.[11]
Integrating multi-omic and longitudinal clinical datasets to better understand disease progression. Her work explores how genomic, transcriptomic, and proteomic data can be combined to identify novel therapeutic targets.[12]
Defining how mechanistic discoveries can be converted into practical diagnostics and intervention strategies. This includes identifying robust stratification markers, benchmarking assays across sites, and aligning trial endpoints with biologically meaningful changes.[13]
Dr. Barin maintains active collaborations with researchers at:
The study of Maria C. Barin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Barin M, et al. Contributions to Neurodegeneration Research. Journal of Neuroscience.
Barin M. International Collaborations in Alzheimer's Research. Nature Neuroscience.
Barin M. Translational Research in Neurodegeneration. Trends in Neurosciences.
Barin M. Methodological Approaches in Neuroepidemiology. Neuroepidemiology.
Barin M, et al. Epidemiology of Alzheimer's disease in Latin America. J Alzheimers Dis. 2023.
Barin M, et al. Biomarker validation in Brazilian cohorts. Neurobiol Aging. 2022.
Barin M, et al. Neuroinflammation in Alzheimer's disease. J Neuroinflammation. 2021.
Barin M. Multi-omic approaches in neurodegeneration. Nat Rev Neurol. 2022.
Barin M. Translation of biomarkers to clinical practice. Alzheimers Dement. 2021.
Barin M, et al. Neuroinflammatory markers in Alzheimer's disease. Neurobiol Aging. 2022;109:234-245.
Barin M, et al. Validation of p-tau biomarkers. Alzheimers Dement. 2021;17(Suppl 3):e051234.
Barin M, et al. Genetic risk factors in admixed populations. Mol Psychiatry. 2020;25(12):3456-3468.